These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32238734)

  • 41. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
    Khemichian S; Terrault NA
    Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic liver disease, thrombocytopenia and procedural bleeding risk; are novel thrombopoietin mimetics the solution?
    Olson SR; Koprowski S; Hum J; McCarty OJT; DeLoughery TG; Shatzel JJ
    Platelets; 2019; 30(6):796-798. PubMed ID: 30422039
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Avoidance of platelet transfusion with readministration of lusutrombopag before radiofrequency ablation in hepatocellular carcinoma:a case report].
    Kotani S; Kohge N; Tsukano K; Ogawa S; Yamanouchi S; Kusunoki R; Aimi M; Miyaoka Y; Fujishiro H
    Nihon Shokakibyo Gakkai Zasshi; 2017; 114(10):1853-1859. PubMed ID: 28978885
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Romiplostim for the management of perioperative thrombocytopenia.
    Al-Samkari H; Marshall AL; Goodarzi K; Kuter DJ
    Br J Haematol; 2018 Jul; 182(1):106-113. PubMed ID: 29767837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
    Bento L; Bastida JM; García-Cadenas I; García-Torres E; Rivera D; Bosch-Vilaseca A; De Miguel C; Martínez-Muñoz ME; Fernández-Avilés F; Roldán E; Chinea A; Yáñez L; Zudaire T; Vaz CP; Espigado I; López J; Valcárcel D; Duarte R; Cabrera R; Herrera C; González-Porras JR; Gutiérrez A; Solano C; Sampol A;
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1825-1831. PubMed ID: 31152794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lusutrombopag (Mulpleta®) treatment in a patient with thrombocytopenia complicated by cirrhosis prior to continuous epidural anesthesia during renal artery embolization: a case report.
    Sasaguri T; Hirakawa N; Uemura S
    JA Clin Rep; 2018 Nov; 4(1):80. PubMed ID: 32025904
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects.
    Katsube T; Ishibashi T; Kano T; Wajima T
    Clin Pharmacokinet; 2016 Nov; 55(11):1423-1433. PubMed ID: 27209291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of Thrombocytopenia in Patients with Chronic Liver Disease.
    Saab S; Brown RS
    Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
    Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T
    Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thrombocytopenia associated with chronic liver disease.
    Afdhal N; McHutchison J; Brown R; Jacobson I; Manns M; Poordad F; Weksler B; Esteban R
    J Hepatol; 2008 Jun; 48(6):1000-7. PubMed ID: 18433919
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pre-procedural use of thrombopoietin-receptor agonists in cirrhosis and severe thrombocytopenia: A systematic review and meta-analysis.
    Rose PD; Au M; Woodman RJ; Tee D; Chinnaratha MA
    Dig Liver Dis; 2021 Nov; 53(11):1396-1403. PubMed ID: 34373229
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.
    Gallo P; Terracciani F; Di Pasquale G; Esposito M; Picardi A; Vespasiani-Gentilucci U
    World J Gastroenterol; 2022 Aug; 28(30):4061-4074. PubMed ID: 36157107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of Food and Calcium Carbonate on the Pharmacokinetics of Lusutrombopag, a Novel Thrombopoietin Receptor Agonist.
    Katsube T; Wajima T; Fukuhara T; Kano T
    Clin Ther; 2019 Sep; 41(9):1747-1754.e2. PubMed ID: 31303281
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New Small Molecule Drugs for Thrombocytopenia: Chemical, Pharmacological, and Therapeutic Use Considerations.
    Clemons Bankston P; Al-Horani RA
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31226783
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoietin.
    Chang FY; Singh N; Gayowski T; Wagener MM; Mietzner SM; Stout JE; Marino IR
    Transplantation; 2000 Jan; 69(1):70-5. PubMed ID: 10653383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure.
    Terrault NA; Hassanein T; Howell CD; Joshi S; Lake J; Sher L; Vargas H; McIntosh J; Tang S; Jenkins TM
    J Hepatol; 2014 Dec; 61(6):1253-9. PubMed ID: 25048952
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
    Makar RS; Zhukov OS; Sahud MA; Kuter DJ
    Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Second-generation thrombopoietin receptor agonists: New players in the management of cirrhotic patients undergoing therapeutic endoscopy?
    Radaelli F; Hassan C; Buscarini E; Dinis-Ribeiro M; Fuccio L
    Dig Liver Dis; 2021 Oct; 53(10):1362-1363. PubMed ID: 34088596
    [No Abstract]   [Full Text] [Related]  

  • 60. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.